Baird Remains Bullish Following Cempra's (CEMP) 4Q; Focus Remains on Solithromycin Launch

February 25, 2016 7:09 AM

Baird maintained an Outperform rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $33.00 (from $38.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found